RedHill Biopharma (RDHL) Market Capitalization (2013 - 2025)

RedHill Biopharma (RDHL) has reported Market Capitalization for 13 consecutive years, with $15.2 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Market Capitalization fell 99.05% year-over-year to $15.2 million in Q4 2025; TTM through Dec 2025 was $15.2 million, a 99.05% decrease from a year earlier, with the FY2025 full-year figure at $15.2 million, down 99.05% from the prior year.
• Market Capitalization was $15.2 million for Q4 2025 at RedHill Biopharma, down from $502.7 million in the prior quarter.
• Over five years, Market Capitalization peaked at $281.1 billion in Q1 2021 and troughed at $15.2 million in Q4 2025.
• A 5-year average of $72.9 billion and a median of $9.5 billion in 2023 frame the typical range for Market Capitalization.
• Across the five-year window, Market Capitalization soared 75.92% in 2021 and plunged 99.05% in 2025, its largest moves.
• Over 5 years, Market Capitalization stood at $135.9 billion in 2021, then plunged by 93.62% to $8.7 billion in 2022, then gained by 9.09% to $9.5 billion in 2023, then slumped by 82.99% to $1.6 billion in 2024, then sank by 99.05% to $15.2 million in 2025.
• The last three Market Capitalization figures came in at $15.2 million (Q4 2025), $502.7 million (Q2 2025), and $1.6 billion (Q4 2024), per Business Quant data.